CellSeed (TSE:7776) Current Deferred Revenue: 円0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7776 CellSeed Inc TSE:7776
52 GF Score
Price 円233.00
GF Value 円145.43
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is CellSeed Current Deferred Revenue?

CellSeed TSE:7776 -0.85% 52 Current Deferred Revenue is 円0.00 Mil as of Mar. 2026. GuruFocus rates TSE:7776 with a GF Score™ of 52/100 and a GF Value™ of 円145.43 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

CellSeed's current deferred revenue for the quarter that ended in Mar. 2026 was 円0.00 Mil.

CellSeed Current Deferred Revenue Related Terms

CellSeed Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for CellSeed's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CellSeed Current Deferred Revenue Chart

CellSeed Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CellSeed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:7776
52GF Score
CellSeed Inc TSE:7776
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of 円0.00 Mil mean?
CellSeed (TSE:7776) has a Current Deferred Revenue of 円0.00 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on CellSeed and its competitors.
Is CellSeed's Current Deferred Revenue too high?
CellSeed's current Current Deferred Revenue is 円0.00 Mil. Overall, CellSeed has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CellSeed's Current Deferred Revenue compare to VRTX and REGN?
CellSeed's Current Deferred Revenue of 円0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on CellSeed and its competitors. CellSeed's current Current Deferred Revenue is 円0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSeed stock overvalued right now?
Based on GuruFocus' analysis, CellSeed (TSE:7776) is currently considered Significantly Overvalued. The stock's GF Value™ is 円145.43, compared to a current price of 円233.00 — trading 60.2% above its estimated fair value. The current Current Deferred Revenue is 円0.00 Mil. CellSeed's overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For CellSeed (TSE:7776), the current Current Deferred Revenue is 円0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CellSeed (TSE:7776) Overvalued in 2026?

Based on GuruFocus' analysis, CellSeed stock appears to be overvalued. The current stock price of 円233.00 is trading 60.2% above its estimated GF Value™ of 円145.43. GuruFocus considers CellSeed to be Significantly Overvalued.

Key valuation signals for TSE:7776:

  • Current Deferred Revenue: 円0.00 Mil
  • GF Value™: 円145.43 vs. price of 円233.00 (60.2% above fair value)
  • GF Score™: 52/100 with 5 warning signs

No single metric tells the full story. See the TSE:7776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CellSeed Business Description

Address 2-5-10 Aomi, Telecom Center Building, 15th Floor (East Wing, Koto-ku, Tokyo, JPN, 135-0064
CellSeed Inc is a Japanese biotechnology company. The company is involved in the research, development, marketing, and sale of cell-sheet regenerative medicines, such as epithelial cell sheets for corneal and esophageal regeneration; regenerated cardiac patches to treat heart diseases; cell sheets for periodontal tissue regeneration; and regenerated cartilage sheets for the treatment of osteoarthritis.
52GF Score

Get the complete analysis for TSE:7776

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円233.00
Price
円145.43
GF Value